Loading...
CKPT logo

Checkpoint Therapeutics, Inc.NasdaqCM:CKPT Stok Raporu

Piyasa Değeri US$356.8m
Hisse Fiyatı
US$4.26
US$4.45
4.3% değerinin altında içsel indirim
1Y127.8%
7D1.7%
1D
Portföy Değeri
​
Görünüm

Checkpoint Therapeutics, Inc.

NasdaqCM:CKPT Stok Raporu

Piyasa değeri: US$356.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Checkpoint Therapeutics (CKPT) Hisse Özeti

Ticari aşamada bir immünoterapi ve hedefe yönelik onkoloji şirketi olan Checkpoint Therapeutics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda solid tümör kanserli hastalar için yeni tedavilerin satın alınması, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay

Ödüller

Adil değer tahminimizden 94.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 37.66% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $41K )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

Son 3 ayda önemli miktarda içeriden satış gerçekleşti


CKPT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Checkpoint Therapeutics, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Checkpoint Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$4.26
52 Haftanın En Yüksek SeviyesiUS$4.50
52 Haftanın En Düşük SeviyesiUS$1.80
Beta1.14
1 Aylık Değişim3.40%
3 Aylık Değişim71.08%
1 Yıllık Değişim127.81%
3 Yıllık Değişim-68.91%
5 Yıllık Değişim-81.23%
Halka arzdan bu yana değişim-91.48%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • Sep 20

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 08

Checkpoint: Strong Data, But Comes With Risks

Summary CKPT produced strong data for cosibelimab. However, data was ex-US and from an open-label trial. There's not much cash at CKPT. Checkpoint Therapeutics (CKPT) produced positive results from the registration trial of cosibelimab in skin cancer, however the stock continues to stay depressed from its November highs. What happened in November, why is it still down, and what can make it go back up again - these are the questions. The funny thing here is that nothing really happened in November. I looked at every possible source of data, and apart from a non-relevant earnings release, there doesn't seem to be any particular event or news that led to the spike and the drop around the first week of November. The only thing that came out was the earnings release, on November 4, and like I said, it contains no clues to the price volatility. I checked insider transaction data, and while the insiders here do not ever buy the stock, there are no large sales around November either. I checked another article by a fellow contributor written around that time, and apart from telling us not to worry, they do not shed much illumination on why the stock fell. There wasn't unusual volume either - a sure sign of price volatility - at that time. However, if you look at the charts vis-a-vis the earnings dates, you will see that the stock peaked exactly on earnings release, and then fell drastically. So my best guess is that investors were looking for more clarity on the cosibelimab data release in the earnings press release, which did not happen, leading to the fall. Recall that data was supposed to have been released by end-2021. Speaking of unusual volume, on January 25, ~25 million shares changed hands on that date, against an average volume of 200k odd shares. These were mostly sells. This means, funds must have offloaded their entire stakes that day, the same day when cosibelimab data came out. Such a huge sell-off must have been what kept the stock subdued despite positive trial data. So we do not see a spike even on positive data release - which should be a lesson for biotech investors who play catalyst-driven stocks. The lesson is this: it is naive to think that a catalyst alone will push a stock up. There's a lot of volatility hidden under the murky waters of biopharma investing, and therefore things aren't so predictable here. Coming to the data itself, cosibelimab is an anti-PD-L1 antibody, and it was administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). Key data were: The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4% (95% CI: 36.0, 59.1) based on independent central review of 78 patients using RECIST 1.1 criteria. The median duration of response ((DOR)) had not yet been reached at the data cut-off point (76% of responses are ongoing). Safety data across 201 patients with advanced cancers enrolled and treated in all cohorts remain consistent with those previously reported, with the majority of treatment-emergent adverse events reported as Grade 1 or 2 in severity. Besides metastatic cSCC, the molecule also had an objective response rate (ORR) of 54.8% in 31 patients with locally advanced cSCC. The company presented competitor data in these two indications. The two approved products are Libtayo and Keytruda. The ORR rates from their pivotal trials are quite similar to cosibelimab's data. However, the company has not provided granularity on complete responses besides saying that they are similar to "what's out there," according to Evaluate. 2020 data did show this to be true. Checkpoint's focus is to get into the PD-L1 market with a lower cost drug. Data is also competitive. However, how the FDA will look at it ultimately decides its fate - and they only have an open label phase 1 trial data here, that too outside the US. Recently, Eli Lilly (LLY) and EQRx (EQRX) have tried to bring Chinese PD-L1 inhibitors into the US market, however, the FDA has not been too kind, at least not with Lilly, slamming them for their single country trials. Those are risk factors for Checkpoint, however its trial, although ex-US, was not single-country, having taken place in 9 different countries including France, Spain and Australia. The company also recently wound down the CONTERNO study, a phase 3 study in lung cancer for cosibelimab, citing the Ukraine war as the reason for unsustainably longer enrollment periods. Besides cosibelimab, Checkpoint has a second asset in phase 3 trial - Olafertinib, an anti-EGFR molecule partnered with other companies in Asia. Unlike other EGFRi like Tagrisso® (osimertinib), which have safety issues like
Seeking Alpha • Aug 12

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Checkpoint Therapeutics press release (NASDAQ:CKPT): Q2 GAAP EPS of -$0.16 in-line. Revenue of $0.02M (-87.5% Y/Y) beats by $0.01M. As of June 30, 2022, Checkpoint’s cash and cash equivalents totaled $30.9 million, compared to $41.5 million at March 31, 2022 and $54.7 million at December 31, 2021, a decrease of $10.6 million for the quarter and a decrease of $23.8 million for the first half of 2022. Shares -0.79% PM.
Analiz Makalesi • May 18

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 18

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter. Cosibelimab regulatory applications are possible because of obtaining a confirmed objective response rate of 47.4% in patients with cutaneous squamous cell carcinoma. Cosibelimab holds the potential to disrupt the $30 billion PD-(L)1 class of drugs. Cosibelimab is also being developed to treat patients with non-small cell lung cancer, with a global market that is expected to grow to $11.87 billion by 2028.
Analiz Makalesi • Feb 15

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 28

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Checkpoint Therapeutics recently announced Cosibelimab hit its primary endpoint with a 47.4% ORR in metastatic cSCC. The company also reported positive safety and tolerability profile. The topline results have encouraged the company to submit a BLA to the FDA later this year. In addition, the company is planning on filing for approval in the EU. If approved, Cosibelimab has a unique profile and competitive pricing that could make it a serious contender in a growing immunotherapy market. The announcement triggered a disappointing spike in the share price. I suspect the market is waiting for additional data and perhaps approval in hand before fully committing to CKPT. I believe the lackluster response to the data has produced a buying opportunity.
Seeking Alpha • Nov 26

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Checkpoint Therapeutics expects to report top-line results before year-end, which could determine if Cosibelimab is ready for regulatory submission that could lead to an approval and commercial launch in 2023. Volatility has the share price, which is making big moves in both directions as we move closer to year-end. Investors need to have a game plan. I believe the recent pullback could be a great opportunity for me to buy ahead of this incredibly potent catalyst.
Analiz Makalesi • Oct 30

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Jul 17

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 14

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data

Checkpoint Therapeutics expects to report Cosibelimab’s top-line data in Q4 of this year. The company anticipates submitting a BLA and MMA next year with a potential launch in 2023. I have pushed CKPT aside several times, but I can no longer ignore its potential upside from Cosibelimab and its potential to disrupt a $25B+ checkpoint market. I review some of Cosibelimab’s data and match it up to some of the market’s leading PD-1 and PD-L1 agents. I reveal my investment strategy and long-term outlook.
Seeking Alpha • Jun 21

Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow

The following slide deck was published by Checkpoint Therapeutics, Inc. in conjunction with this event.

Hissedar Getirileri

CKPTUS BiotechsUS Pazar
7D1.7%1.2%1.0%
1Y127.8%34.9%28.7%

Getiri vs. Endüstri: CKPT geçen yıl % 34.9 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: CKPT geçen yıl % 28.7 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is CKPT's price volatile compared to industry and market?
CKPT volatility
CKPT Average Weekly Movement17.7%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: CKPT hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: CKPT 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 12% dan 18% a yükseldi.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
201424James Olivierocheckpointtx.com

Ticari aşamada bir immünoterapi ve hedefe yönelik onkoloji şirketi olan Checkpoint Therapeutics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda solid tümör kanserli hastalar için yeni tedavilerin edinilmesi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirketin lider antikor ürün adayı, seçilmiş tekrarlayan veya metastatik kanserli hastaları tedavi etmek için Faz 1 klinik çalışmasında olan UNLOXCYT; ve hematolojik maligniteler ve solid tümörler için klinik öncesi çalışmalarda bir ürün adayı olan CK-302'dir. Ayrıca, metastatik küçük hücreli dışı akciğer kanseri olan yetişkin hastaların tedavisi için Faz 3 klinik çalışmalarında olan Olafertinib; çeşitli ileri ve metastatik solid tümör kanserlerinin tedavisi için CK-103; ve CAIX eksprese eden hücreleri tanımak ve onları antikora bağlı hücresel sitotoksisite ve komplemana bağlı sitotoksisite yoluyla öldürmek için klinik öncesi çalışmalarda bir ürün adayı olan Anti-Karbonik Anhidraz IX (CAIX) antikorunu geliştirmektedir.

Checkpoint Therapeutics, Inc. Temel Bilgiler Özeti

Checkpoint Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CKPT temel i̇stati̇sti̇kler
Piyasa değeriUS$356.83m
Kazançlar(TTM)-US$56.51m
Gelir(TTM)US$41.00k
8,703x
P/S Oranı
-6.3x
F/K Oranı

CKPT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CKPT gelir tablosu (TTM)
GelirUS$41.00k
Gelir MaliyetiUS$31.44m
Brüt Kâr-US$31.40m
Diğer GiderlerUS$25.11m
Kazançlar-US$56.51m

Son Raporlanan Kazançlar

Mar 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-0.67
Brüt Marj-76,590.24%
Net Kâr Marjı-137,821.95%
Borç/Özkaynak Oranı0%

CKPT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/06/03 23:39
Gün Sonu Hisse Fiyatı2025/05/29 00:00
Kazançlar2025/03/31
Yıllık Kazançlar2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Checkpoint Therapeutics, Inc. 3 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.